Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Adverse drug reactions

Link between pioglitazone and bladder cancer risk confirmed

Researchers confirmed that the risk of bladder cancer increased with both the dose and duration of pioglitazone treatment.

Use of the antidiabetic drug pioglitazone is associated with an increased risk of bladder cancer, according to new research published in the BMJ.

Over a mean follow-up of 4.7 years, patients who received pioglitazone were 63% more likely to develop bladder cancer than diabetic patients who received no thiazolidinediones. But the use of a similar drug in this class, rosiglitazone, was not associated with the risk of bladder cancer.

“Given their similarities, it is unlikely that confounding by indication or detection bias can explain the association observed with pioglitazone,” write the researchers, led by Marco Tuccori at McGill University, Montreal.

The risk of bladder cancer increased with both the dose and duration of pioglitazone treatment. However, the overall risk of the disease was low: a total of 622 diagnoses were detected with an incidence rate of 88.9 versus 121.0 per 100,000 patient years in unexposed versus pioglitazone-treated patients.

The research[1], which used data from a UK general practice database, included 145,806 people receiving antidiabetic drugs for the first time between 2000 (the year that pioglitazone and rosiglitazone entered the UK market) and 2013.

An association between pioglitazone and bladder cancer was first detected in 2005, but not all observational studies have replicated the finding. After carrying out a safety review in 2011, the European Medicines Agency cautioned doctors against prescribing the drug to patients at risk of bladder cancer.

In an accompanying editorial[2], Victor Montori from the Mayo Clinic describes the evidence linking the drug to bladder cancer as “substantial and fairly consistent”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20200942

Readers' comments (1)

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • X-ray showing a tumour in urinary bladder

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.